T
TriSalus Life Sciences, Inc. (TLSI)
NGM – Real vaqt narxi. Valyuta: USD
4.56
+0.02 (0.44%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.12
-0.44 (-9.65%)
Bozor oldidan: May 13, 2026, 7:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.56
+0.02 (0.44%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.12
-0.44 (-9.65%)
Bozor oldidan: May 13, 2026, 7:00 AM EDT
TriSalus Life Sciences, Inc. Qo'shma Shtatlarda davolash qiyin bo'lgan jigar va oshqozon osti bezi saratoni bilan og'rigan bemorlar uchun natijalarni yaxshilash maqsadida dorilarni etkazib berish texnologiyasi platformasi va immunoonkologik dorilarni tadqiq qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya bosim bilan ta'minlangan dorilarni etkazib berish (PEDD) infuzion tizimlarini taklif etadi, masalan, TriNav infuzion tizimi, u jigar saratoni va metastazlari bilan og'rigan bemorlar uchun transarterial radioembolizatsiya va kemoembolizatsiya muolajalarida qo'llaniladi; va oshqozon osti bezi retrograd venoz infuziya moslamasi, u mahalliy rivojlangan oshqozon osti bezi saratonini davolash uchun 1-bosqich klinik sinovdan o'tmoqda. Kompaniya, shuningdek, uveal melanoma, intrahepatik xolangiokarsinoma, gepatotsellyulyar karsinoma va oshqozon osti bezi saratonini davolash uchun 1-bosqich klinik sinovda bo'lgan nelitolimod nomli tadqiqot immunoterapiyasini ishlab chiqmoqda. Kompaniya interventsion radiologlar, IR texniklari, tibbiy onkologlar, hamshiralik yordami va qiymatni tahlil qilish qo'mitasi xodimlariga xizmat ko'rsatadi. Kompaniya 2009 yilda tashkil etilgan va shtab-kvartirasi Koloradoning Vestminster shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Andrea Marasso | Vice President of Marketing |
| Dr. Bryan F. Cox Ph.D. | Chief of Research |
| Dr. Richard Marshall M.D. | Medical Director |
| Dr. Richard B. Marshak M.B.A., VMD | Chief Commercial Officer |
| Mr. David B. Patience | Chief Financial Officer |
| Ms. Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Ms. Jodi Devlin | Chief of Clinical Strategy & Operations |
| Ms. Mary T. Szela B.S.N., M.B.A. | CEO, President & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 10-Q | tlsi-20260331.htm |
| 2026-04-29 | 8-K | tlsi-20260424.htm |
| 2026-04-07 | 8-K | tlsi-20260401.htm |
| 2026-03-31 | DEF 14A | tlsi-20260330.htm |
| 2026-03-10 | S-8 | forms-8march2026.htm |
| 2026-03-05 | 10-K | tlsi-20251231.htm |
| 2026-02-20 | 8-K | form8-k.htm |
| 2026-02-09 | 8-K | tlsi-20260203.htm |
| 2026-01-12 | 8-K | tlsi-20260112.htm |
| 2025-12-02 | CORRESP | filename1.htm |